project id: TCGA-BLCA; case submitter id: TCGA-5N-A9KI; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.94; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.37; rna integrity number: 8.0; age at index: 76; days to birth: -27777; days to death: 76; ethnicity: not hispanic or latino; gender: female; race: white; vital status: Dead; year of birth: 1935; year of death: 2011; age at diagnosis: 27777; ajcc clinical t: T4a; ajcc pathologic m: MX; ajcc pathologic n: NX; ajcc pathologic stage: Stage III; ajcc pathologic t: T4; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; icd 10 code: C67.9; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Bladder, NOS; synchronous malignancy: No; tissue or organ of origin: Bladder, NOS; tumor grade: Not Reported; year of diagnosis: 2011; treatment or therapy: no; alcohol history: Not Reported; cigarettes per day: 3.287671232876712; pack years smoked: 60.0; is ffpe: false; composition: Not Reported; days to collection: 903; days to sample procurement: 0; initial weight: 162.0; portion submitter id: TCGA-5N-A9KI-01A-31; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 1.0; percent necrosis: 1.0; percent neutrophil infiltration: 5.0; percent normal cells: 0.0; percent stromal cells: 19.0; percent tumor cells: 80.0; percent tumor nuclei: 80.0;